In What is BPC-157?, we covered what this peptide is, why it is mainly associated with tendon healing, and how little we still know about its effects in humans. Here, we will go straight to the practical questions: how much BPC-157 people use, how often they use it, and how long a cycle typically lasts.
Quick summary (TL;DR)
If you only want to know how people in the community use BPC-157 most often:
- How much and how often: the most common community pattern is 500 µg once daily. Forum users also report splitting this into 250 µg in the morning and 250 µg in the evening, or following a five-days-on, two-days-off schedule. A more conservative option is 250 µg daily.
- For how long: most often 8 to 12 weeks. Shorter cycles of 4 to 8 weeks frequently appear on older forums.
- How: most often subcutaneously, meaning into the fat beneath the skin.
- Where: the abdomen is a common choice. Some people in the community prefer subcutaneous injection near the affected area if there is safely accessible subcutaneous fat there—not directly into a tendon, joint, or muscle.
Why people use BPC-157
The most common reasons are practical and mostly relate to the musculoskeletal system:
- persistent tendon problems, such as tennis elbow or Achilles tendon issues;
- ligament and joint injuries;
- muscle injuries and overuse;
- recovery after surgery;
- chronic pain and irritation associated with training;
- slower overall recovery;
- less commonly, stomach and intestinal problems.
In the community survey, 66% of respondents reported musculoskeletal injury as their main reason for use, 25% reported pain or inflammation, and 15% reported digestive problems.1 Some users combine BPC-157 with TB-500, but this makes it practically impossible to determine which substance, if either, produced the result.
What respondents reported: dose, frequency, and cycle length
The largest community survey we found included 613 BPC-157 users. Not everyone answered every question, and some free-text responses could not be evaluated numerically, so the number of respondents differs between the tables.1
Dose per administration
A numerical dose could be evaluated for 371 respondents. The median was 500 µg per administration.
| Dose per administration | Respondents | Share |
|---|---|---|
| Less than 250 µg | 17 | 4.6% |
| 250–499 µg | 70 | 18.9% |
| 500–1,000 µg | 212 | 57.1% |
| 1,001–2,000 µg | 19 | 5.1% |
| 2,001–5,000 µg | 26 | 7.0% |
| More than 5,000 µg | 27 | 7.3% |
For the highest values, the authors themselves note the possibility of unit errors or confusion between a dose per administration and a daily or weekly total. Community doses are normally given in micrograms (µg or mcg), not milligrams. 500 mg is one thousand times 500 µg.
How often they used BPC-157
| Frequency | Respondents | Share of 613 users |
|---|---|---|
| Every day | 378 | 61.7% |
| 5× per week | 149 | 24.3% |
| 2–3× per week | 52 | 8.5% |
| Once per week | 6 | 1.0% |
| Other schedule | 22 | 3.6% |
| No response | 6 | 1.0% |
Daily use clearly predominated. Five days on and two days off was the second most common schedule, but the survey does not show that taking weekends off improves the effect or prevents tolerance.
How long a cycle lasted
Cycle length could be evaluated numerically for 441 respondents. The median was 8.7 weeks, and the middle 50% of responses ranged from 6 to 16 weeks.
| Duration of use | Respondents | Share of 441 responses |
|---|---|---|
| Less than 4 weeks | 56 | 12.7% |
| 4–7 weeks | 70 | 15.9% |
| 8–11 weeks | 128 | 29.0% |
| 12–25 weeks | 135 | 30.6% |
| 26–51 weeks | 18 | 4.1% |
| 52 weeks or more | 34 | 7.7% |
Most responses fell into the 8–11 and 12–25 week ranges. The second interval is several times wider, however, so it does not mean that a typical cycle lasts as long as 25 weeks. The median was 8.7 weeks, and the survey itself identifies approximately 8 to 12 weeks as the most common pattern. Four to six weeks is more representative of shorter community cycles.
With an injury, it is also difficult to know when the tissue has genuinely healed. Less pain does not necessarily mean that a tendon or ligament is ready for full loading again. BPC-157 should therefore not be used as a substitute for rehabilitation or as a reason to return prematurely to the activity that caused the problem in the first place.
How and where BPC-157 is administered
Injection is by far the most common route. Within the community, this usually means subcutaneous injection into the fat beneath the skin. In the survey, 92% of respondents reported injection—subcutaneous or intramuscular—while 6% reported oral use and only a handful used a nasal spray.1
BPC-157 capsules and tablets are also sold online. For people who are afraid of needles, this is understandably a more appealing option. In the community, oral BPC-157 is used mainly for stomach and intestinal problems, where it could act locally within the digestive tract. We do not know how much BPC-157 is absorbed after oral use in humans or whether it reaches meaningful systemic exposure. It therefore cannot be assumed that a tablet will replace an injection for tendons, ligaments, and other distant tissues.2
In theory, it should not matter where BPC-157 is injected, and the abdomen is a common choice. Some people, however, report better results from subcutaneous injection near the affected area.3 We have no direct comparison, but if there is enough subcutaneous fat nearby, it may be worth trying: if there is no local difference, the peptide should simply be absorbed as it would be from the abdomen. This does not mean injecting directly into a tendon, joint, or muscle.
How long BPC-157 works
Some people on forums report continuing to feel an effect for weeks after the end of a cycle. For others, the problem returns immediately or within two to three weeks, while some report improvement lasting months and, in rare cases, even years.4 We do not know what a reliable typical duration would be.
BPC-157 probably does not remain in the bloodstream for long. In rats and dogs, its half-life was less than 30 minutes, and it was no longer detectable in plasma after four hours.5 We do not have comparable human data, and a short half-life does not tell us how long any resulting effect might last.
One possible explanation is straightforward: if BPC-157 genuinely helps tissue heal, the result could remain after the peptide itself has disappeared from the blood. If it only temporarily affects pain or inflammation, the problem may return. We do not yet know which explanation reflects reality or why the effect is sometimes reported to last so long.
Risks in practice
We cover the full safety context in What is BPC-157?. For practical use, these are the most important points:
- the product may contain a different amount or a different substance from what the label states;
- sterility and the risk of contamination are critical for an injectable product;
- the community survey most often recorded injection-site reactions, and less often digestive problems, changes in blood pressure, swelling, mood changes, and palpitations;1
- we do not know the long-term risks of repeated cycles;
- BPC-157 is prohibited for competitive athletes under WADA rules.6
The biggest unknown is not only whether BPC-157 works. We know just as little about who will not benefit, who it may harm, and whether increasing the dose provides anything beyond greater exposure to an unverified product.
What to take away
Community practice has settled around 500 µg daily, usually every day. In the survey, the median cycle length was 8.7 weeks; forums report shorter cycles of around 4 to 8 weeks as well as substantially longer use. That is the most accurate answer to the question of how people use BPC-157.
This is not the same as optimal dosing. We do not know whether 500 µg is better than 250 µg, whether split dosing provides an advantage, or whether local injection truly works better than injecting into the abdomen. We have a fairly good picture of what the community does. Why it sometimes appears to work in their experience, and why the result persists after stopping in some people, remain open questions.
Sources
-
Peptide Safety Initiative. Real-World Use and Tolerability of BPC-157: An Observational Analysis of 619 Self-Reported User and Clinician Survey Responses. April 13, 2026. A voluntary, cross-sectional community survey of 613 users and 6 clinicians; not a controlled or peer-reviewed clinical study. BPC-157 Observational Survey Analysis. ↩ ↩2 ↩3 ↩4
-
In its assessment, the FDA found no studies examining oral administration of BPC-157 in humans and no human pharmacokinetic data that could be used to determine its absorption and systemic exposure. FDA Briefing Document: BPC-157. ↩
-
Examples of community discussion, not a clinical comparison: users describe both subjectively better results from local injection and no difference compared with injection into the abdomen. BPC-157 / TB-500—local injection vs systemic. ↩
-
Examples of differing experiences after stopping, not evidence of a typical duration of effect: pain returning after stopping, results persisting or partially reversing, and pain returning after approximately three weeks. ↩
-
He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. PMID 36588717. DOI: 10.3389/fphar.2022.1026182. The study examined intravenous and intramuscular administration in animals, not subcutaneous administration in humans. ↩
-
World Anti-Doping Agency. 2026 List of Prohibited Substances and Methods. BPC-157 falls under category S0—Non-Approved Substances. WADA Prohibited List. ↩